泰豪生物完成新一轮融资，董事长王磊持股35%

Core Insights - Beijing Taihao Biotechnology Co., Ltd. has successfully completed a new round of financing, exclusively funded by Linyi Linshu Emerging Industry Fund managed by Shanda Investment Management [1] - The raised funds will be primarily used to accelerate the registration application process for the company's core product, a microfluidic nucleic acid rapid detection kit for infectious diseases, and to initiate the construction of a modern production base [1] Company Overview - Taihao Biotechnology was established in 2021, with a registered capital of 1.736 million yuan, and focuses on developing intelligent rapid detection devices in the field of biological molecular detection based on microfluidic technology [1] - The company possesses unique technical routes and experience in the production and manufacturing of microfluidic chips, covering the entire business chain from chip design, reagent and instrument development to production line construction and product manufacturing [1] - The actual controller of Taihao Biotechnology is Wang Lei, who holds a total shareholding ratio of 34.56% and currently serves as the chairman and manager of the company [1]